

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT06925542

Status	RECRUITING
Phase	Phase 1
Sponsor	CRISPR Therapeutics
Enrollment	80 participants

Key Eligibility Criteria

Inclusion (12)

- Age ≥18 years and < 70 years of age.
 - Subjects must voluntarily sign a written informed consent and be willing and able to comply with all study requirements.
 - Adequate hematologic, renal, liver, cardiac and pulmonary organ function.
 - Subjects must agree to use acceptable methods of contraception.
 - Willing and able to comply with scheduled visits, treatment plan, laboratory tests, contraceptive guidelines, and other study procedures.
- ... and 7 more (see full listing online)

Exclusion (13)

- Prior anti-CD19 therapy or any gene therapy/genetically modified cell therapy.
 - Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant.
 - Severe active or history of central nervous (CNS) involvement.
 - History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease or any autoimmune disease with CNS involvement other than SLE, SSc or IIM.
 - Mixed connective tissue disease with no clear predominant disease.
- ... and 8 more (see full listing online)

Locations (8 total)

Research Site 4, Redwood City, California, United States
Research Site 2, Chicago, Illinois, United States
Research Site 8, Iowa City, Iowa, United States
... and 5 more locations